Related Experiment Video
Updated: Aug 18, 2025

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
Published on: August 17, 2022
Myocarditis Related to COVID-19 and SARS-CoV-2 Vaccination
Ana I Molina-Ramos1,2, Elisabeth Gómez-Moyano3, Jorge Rodríguez-Capitán1,2
1Centro de Investigación en Red de Enfermedades Cardiovasculares (CIBERCV), Cardiology Department, Hospital Universitario Virgen de la Victoria, 29010 Málaga, Spain.
Insights
Myocarditis, a heart condition, can be a consequence of COVID-19 and mRNA vaccines. This review examines its epidemiology and prognosis, balancing risks against vaccination benefits.
Area of Science:
- Cardiology
- Infectious Diseases
- Immunology
Background:
- Coronavirus disease 2019 (COVID-19) has caused significant global morbidity and mortality.
- Myocarditis, a heart inflammation, is a notable consequence of COVID-19 with potentially poor prognosis.
- The epidemiology and specific prognosis of COVID-19-related myocarditis remain largely unknown.
Purpose of the Study:
- To review the etiopathogenesis, epidemiology, clinical features, diagnosis, prognosis, and treatment of myocarditis associated with SARS-CoV-2 infection.
- To analyze myocarditis occurring secondary to COVID-19 mRNA vaccination.
- To contextualize myocarditis risk within the overall public health benefits of COVID-19 vaccination.
Main Methods:
- This study is a narrative review.
- Literature search on SARS-CoV-2, COVID-19, myocarditis, and mRNA vaccines.
- Synthesis of existing data on the topic.
Main Results:
- Myocarditis is a recognized complication of COVID-19.
- Myocarditis is also a rare adverse event associated with mRNA COVID-19 vaccines.
- Data on the specific epidemiology and long-term prognosis of COVID-19-related myocarditis is still emerging.
Conclusions:
- Myocarditis requires consideration as a potential consequence of both COVID-19 and its vaccination.
- The benefits of COVID-19 vaccination are substantial and should be weighed against the rare risk of myocarditis.
- Further research is needed to fully elucidate the epidemiology and prognosis of COVID-19-associated myocarditis.
Abstract:
The coronavirus disease of 2019 (COVID-19) has been a cause of significant morbidity and mortality worldwide. Among the short- and long-term consequences of COVID-19, myocarditis is a disease to be taken into consideration. Myocarditis, in general, is related to a poor prognosis. However, the epidemiology and prognosis of myocarditis related to COVID-19 are currently unknown. While vaccination against COVID-19 is of great benefit at a public health level, the risk of myocarditis should be considered in the context of the global benefits of vaccination. In this narrative review, we will summarize the etiopathogenic bases, the epidemiology, the clinical manifestations, the course, diagnosis, prognosis, and the treatment of myocarditis related to SARS-CoV-2, as well as myocarditis secondary to mRNA vaccines.
More Related Videos
Related Concept Videos
Myocarditis I: Introduction
Myocarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis IV: Nursing Management
Pericarditis I: Introduction
Pericarditis II: Clinical Features and Diagnostic Tests

